Michael Hayden

Pridopidine application beyond Huntington’s disease 3:03
Pridopidine application beyond Huntington’s disease
Michael Hayden • 27 Sep 2022
PROOF-HD: Phase III trial of oral S1R agonist pridopidine for the treatment of Huntington’s disease 5:38
PROOF-HD: Phase III trial of oral S1R agonist pridopidine for the treatment of Huntington’s disease
Michael Hayden • 27 Sep 2022
Does loss of wildtype huntingtin function contribute to Huntington’s disease? 1:18
Does loss of wildtype huntingtin function contribute to Huntington’s disease?
Michael Hayden • 27 Sep 2022
Huntingtin lowering: what level of wildtype protein knockdown is safe? 2:21
Huntingtin lowering: what level of wildtype protein knockdown is safe?
Michael Hayden • 27 Sep 2022
Somatic expansion as a novel therapeutic approach for Huntington’s disease 2:54
Somatic expansion as a novel therapeutic approach for Huntington’s disease
Michael Hayden • 27 Sep 2022
The role of post-translational modifications in Huntington’s disease 2:22
The role of post-translational modifications in Huntington’s disease
Michael Hayden • 27 Sep 2022
The content of VJNeurology is intended for healthcare professionals